Asia Pacific Single-cell Analysis Market Valued at USD 1,375 million by 2025

Asia Pacific Single-cell Analysis Market by Cell Type (Human, Animal, Microbial), Product (Reagent, Assays, Instruments), Technique (Flow Cytometry, NGS, PCR), Application (Cancer, Stemcell, IVF), End User (Academic, Research Labs) - Forecast to 2025

[212 Pages Report] The Asia Pacific Single-Cell Analysis Market is projected to reach USD 1,375 million by 2025 from USD 550 million in 2020, at a CAGR of 20.1%. Asia Pacific single-cell analysis market growth is driven by the growing focus on personalized medicine, increasing RD in the pharmaceutical and biotechnology industries for complex diseases, growth in stem cell research, and the increasing frequency of pandemics.


Download PDF Brochure:

Market Dynamics


Pharmaceutical and biotechnology companies utilize single-cell analysis products to achieve their clinical research goals. Biopharmaceutical companies focus on developing targeted therapies, especially for the treatment of cancer, complex diseases, and rare genetic disorders. As companies are focusing on developing targeted therapies, the need for single-cell analysis products has become imperative for determining the genetic profile of patients enrolled in clinical trials. Similarly, pharmaceutical companies are utilizing single-cell analysis instruments such as NGS technologies for biomarker research, which is a segment that has the potential to grow at a high CAGR in the coming years.


Single-cell sequencing (SCS) helps understand the transcriptional stochasticity and cellular heterogeneity in more detail. It assists in the investigation of small groups of differentiating cells and circulating tumor cells. It also demonstrates the heterogeneity of gene expressions, interaction and regulations of gene regulatory networks, characteristics of putative cancer stem cells, gene expression profiles of intracellular compartments, mRNA locations, and allele-specific gene expression. Advancements in single-cell sequencing have improved the detection and analysis of infectious disease outbreaks, antibiotic drug-resistant strains, food-borne pathogens, and microbial diversities in the environment.


Currently, the isolation and analysis of circulating tumor cells (CTCs) and cells that are present in low quantities in the body is a major challenge faced by researchers and clinicians. Advances in microfluidics technology have provided robust solutions for the isolation and analysis of single cells. Moreover, microfluidic chips are easy to use and provide reliable and efficient isolation of single cells from a small sample volume.

Request 10% Customization:

 In 2019, consumables segment accounted for the largest share of the Asia Pacific single-cell analysis industry, by product

Based on product, the Asia Pacific single-cell analysis market is segmented into consumables and instruments. The consumables segment includes beads, microplates, reagents, assay kits, and other consumables. The instruments segment includes flow cytometers, NGS systems, PCR instruments, spectrophotometers, microscopes, cell counters, HCS systems, microarrays, and other instruments. The consumables segment accounted for the largest market share in 2019. This segment is also expected to register the highest CAGR during the forecast period. The large share and high growth of this segment can primarily be attributed to the frequent purchase of these products as compared to instruments, which are considered as a one-time investment, and their wide applications in research and exosome analysis.

In 2019, human cells segment accounted for the largest share in the market, by cell type

The Asia Pacific single-cell analysis market is segmented into human cells, animal cells, and microbial cells based on cell type. The human cells segment accounted for the largest market share in 2019, owing to the high adoption of human cells to develop novel cancer therapies.

Japan is the largest market for single-cell analysis

The Asia Pacific single-cell analysis market is segmented into Japan, China, India, South Korea, Singapore, Australia, Southeast Asia, and the Rest of Asia Pacific. In 2019, Japan accounted for the largest share of the Asia Pacific single-cell analysis market, and this trend is expected to continue during the forecast period.

In terms of market share, China closely followed Japan in 2019. However, in the next five years, the share of Japan is expected to increase in the APAC single-cell analysis market as it is estimated to witness higher CAGR than China. This can be attributed to the large geriatric population, increasing life science research activities, and growing focus on personalized medicine in Japan.

Recent Developments:

  • In September 2020, Lonza (Switzerland) launched Promega Corporation (US) launched the Spectrum Compact CE System.
  • In March 2020, Fluidigm Corporation (US) opened a new Center of Excellence (CoE) for Imaging Mass Cytometry (IMC) in Singapore, together with the Singapore Immunology Network (SIgN), part of the Agency for Science, Technology and Research.
  • In January 2020, Takara Bio (Japan) opened the Center for Gene and Cell Processing II for the research and manufacturing of regenerative medicine products in Kusatsu.

Frequently Asked Questions (FAQ):

  • What are the recent trends affecting the Asia Pacific single-cell analysis market?
  • What are the different cell types used for single-cell analysis?
  • Who are the key players in the Asia Pacific single-cell analysis market?
  • Who are the key end-users of the Asia Pacific single-cell analysis market?
  • Which country is lucrative for the Asia Pacific single-cell analysis market?

Key Players:

Becton, Dickinson and Company (US), Danaher Corporation (US), Merck Millipore (US), QIAGEN N.V. (Netherlands), Thermo Fisher Scientific, Inc. (US), General Electric Company (US), Promega Corporation (US), Illumina, Inc. (US), Bio-Rad Laboratories (US), Fluidigm Corporation (US), Agilent Technologies, Inc. (US)

Report Link: ( Asia Pacific Single-cell Analysis Market )

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies' revenues. Currently servicing 7500 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the "Growth Engagement Model - GEM". The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write "Attack, avoid and defend" strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets's flagship competitive intelligence and market research platform, "Knowledgestore" connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.


Mr. Aashish Mehra

MarketsandMarkets™ INC.

630 Dundee Road

Suite 430

Northbrook, IL 60062

USA: 1-888-600-6441

Email: [email protected]

Research Insight:

 Visit Our Web Site:

 Content Source:


87 Blog posts